WILSONVILLE, Ore.--(BUSINESS WIRE)--Amedex Therapeutics, Inc.™ (ATI), formerly Nu Pharmas, Inc., a biopharmaceutical company developing its NuBiotics portfolio of unique anti-infective products targeted to bacterial infections, encompassing antibiotic resistant bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and also certain viral indications including avian influenza, Epstein Barr Virus (EBV) and hepatitis B and C, announced today that it has been issued a fourth NuBiotics patent by the U.S. patent office.
